Currently submitted to: JMIR Public Health and Surveillance
Date Submitted: Apr 28, 2026
Open Peer Review Period: Apr 29, 2026 - Jun 24, 2026
(currently open for review)
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Incretin-Based Therapeutics: A Dual-Pronged Evaluation of Global Health Impact and Clinical Viability
ABSTRACT
Obesity has become one of the main public health problems worldwide, due to its association with an increased risk of cardiovascular diseases and type 2 diabetes mellitus. In this context, incretin-based therapies, particularly those that are GLP-1 receptor agonists, are revolutionizing and transforming metabolic management. This is due to their multiple effects, including glycemic regulation, appetite reduction, and assistance in body weight loss, in addition to lowering cardiovascular risk. However, their use presents a series of challenges, both clinical and practical. Among these are the reduction of lean body mass, the need for long-term use, and the potential for weight regain after discontinuation of the medication. Furthermore, their high cost limits their widespread availability globally, making access difficult for countries with limited resources.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.